Ken Griffin Esperion Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 41,100 shares of ESPR stock, worth $71,925. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,100

Previous 147,500 72.14%

Holding current value

$71,925

Previous $395,000 76.96%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.84 - $3.24 $3.39 Million - $5.96 Million	-1,840,433 Reduced 54.74%	1,521,777 $3.38 Million
Q1 2024 May 15, 2024	BUY	$2.02 - $3.02 $5.86 Million - $8.76 Million	2,899,928 Added 627.31%	3,362,210 $9.01 Million
Q4 2023 Feb 14, 2024	SELL	$0.73 - $3.08 $138,164 - $582,939	-189,266 Reduced 29.05%	462,282 $1.38 Million
Q3 2023 Nov 14, 2023	SELL	$0.96 - $1.79 $53,017 - $98,856	-55,227 Reduced 7.81%	651,548 $638,000
Q2 2023 Aug 14, 2023	SELL	$1.2 - $1.76 $37,687 - $55,274	-31,406 Reduced 4.25%	706,775 $982,000
Q1 2023 May 15, 2023	SELL	$1.46 - $7.3 $1.19 Million - $5.93 Million	-811,815 Reduced 52.38%	738,181 $1.17 Million
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $5.27 Million - $8.8 Million	1,035,258 Added 201.12%	1,549,996 $9.66 Million
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $2.25 Million - $3.36 Million	413,144 Added 406.66%	514,738 $3.45 Million
Q2 2022 Aug 15, 2022	BUY	$4.77 - $6.67 $297,056 - $415,380	62,276 Added 158.39%	101,594 $646,000
Q1 2022 May 16, 2022	SELL	$3.34 - $5.56 $642,946 - $1.07 Million	-192,499 Reduced 83.04%	39,318 $182,000
Q4 2021 Feb 14, 2022	BUY	$4.81 - $11.92 $614,958 - $1.52 Million	127,850 Added 122.97%	231,817 $1.16 Million
Q3 2021 Nov 15, 2021	BUY	$11.34 - $21.37 $464,418 - $875,186	40,954 Added 64.99%	103,967 $1.25 Million
Q2 2021 Aug 16, 2021	BUY	$19.4 - $28.71 $184,280 - $272,716	9,499 Added 17.75%	63,013 $1.33 Million
Q1 2021 May 17, 2021	SELL	$25.12 - $36.89 $3.84 Million - $5.64 Million	-152,860 Reduced 74.07%	53,514 $1.5 Million
Q4 2020 Feb 16, 2021	BUY	$24.2 - $35.76 $4.12 Million - $6.09 Million	170,207 Added 470.61%	206,374 $5.37 Million
Q3 2020 Nov 16, 2020	SELL	$31.18 - $52.71 $1.4 Million - $2.37 Million	-44,871 Reduced 55.37%	36,167 $1.34 Million
Q2 2020 Aug 14, 2020	SELL	$30.04 - $51.31 $3.28 Million - $5.59 Million	-109,029 Reduced 57.36%	81,038 $4.16 Million
Q1 2020 May 15, 2020	BUY	$27.44 - $73.84 $692,640 - $1.86 Million	25,242 Added 15.31%	190,067 $5.99 Million
Q4 2019 Feb 14, 2020	SELL	$35.4 - $59.82 $4.85 Million - $8.2 Million	-137,039 Reduced 45.4%	164,825 $9.83 Million
Q3 2019 Nov 14, 2019	BUY	$34.47 - $47.53 $3.21 Million - $4.43 Million	93,101 Added 44.6%	301,864 $11.1 Million
Q2 2019 Aug 14, 2019	BUY	$40.1 - $52.33 $4.36 Million - $5.7 Million	108,847 Added 108.94%	208,763 $9.71 Million
Q1 2019 May 15, 2019	BUY	$40.11 - $53.57 $1.48 Million - $1.98 Million	36,971 Added 58.74%	99,916 $0
Q4 2018 Feb 14, 2019	BUY	$36.99 - $59.11 $56,039 - $89,551	1,515 Added 2.47%	62,945 $2.9 Million
Q3 2018 Nov 13, 2018	BUY	$40.74 - $51.41 $1.81 Million - $2.29 Million	44,487 Added 262.57%	61,430 $0
Q2 2018 Aug 10, 2018	SELL	$36.2 - $76.4 $16 Million - $33.7 Million	-441,084 Reduced 96.3%	16,943 $0
Q1 2018 May 11, 2018	BUY	$65.94 - $80.76 $18.7 Million - $23 Million	284,335 Added 163.7%	458,027 $33.1 Million
Q4 2017 Feb 09, 2018	BUY	$43.47 - $67.43 $5.01 Million - $7.78 Million	115,360 Added 197.76%	173,692 $11.4 Million
Q3 2017 Nov 09, 2017	BUY	$43.8 - $52.77 $2.55 Million - $3.08 Million	58,332	58,332 $2.92 Million

Others Institutions Holding ESPR

# of Institutions

199

Shares Held

136M

Call Options Held

2.72M

Put Options Held

1.3M

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $116M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account